Healthcare Global Enterprises Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹585Cr
- +18.3% YoY
- +4.8% QoQ
- Net profit
- ₹7Cr
- −71.1% YoY
- −12.6% QoQ
- Margin
- 18.05%
- −0.6 pp YoY
- +2.2 pp QoQ
Guidance rank: #29 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Healthcare Global Enterprises Ltd Q4 FY25 key numbers
- Revenue
- FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores.
As stated in Healthcare Global Enterprises Ltd's Q4 FY25 earnings call transcript · published 8 Aug 2026. Reported figures, not investment advice.
The short version
FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. HCG expects continued strong revenue and EBITDA growth in FY '26, building on a 16-18% revenue growth in FY '25 and a 44% EBITDA increase in emerging centers.
From Healthcare Global Enterprises Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores.
- Excluding Milann, core HCG centers saw 17% revenue growth and 17% EBITDA growth in FY '25.
- Outpatient footfall increased by 13.8%; chemotherapy sessions grew 24%, indicating higher patient demand.
- Emerging centers delivered 32% revenue growth with improving EBITDA margins, expected to boost overall margins.
- Digital revenue doubled in FY '25; with efforts to scale digital channels further expected to contribute significantly to top-line growth.
- New facilities: flagship 189-bed center in Ahmedabad operationalized; two new hospitals in Bangalore to come online in FY '26 to tap new markets and enhance capacity.
- Plans to operationalize over 900 beds across the network within 3 years including 350 beds invested but not yet operational.
2 more points from Healthcare Global Enterprises Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Healthcare Global Enterprises Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 Capex planned at approximately INR 286 crores focused on network expansion and technology upgrades, including existing centers in Bangalore and Cuttack.
- Addition of over 900 beds across the network within the next 3 years, including 350 beds fully invested but not yet operational.
- Investment in advanced technologies such as linear accelerator (LINAC) machines, PET-CT scanners, and robotic surgery platforms to enhance precision cancer care.
- Two new hospitals to commence operations in Bangalore in FY '26: one in North Bangalore (second half of FY '26) and another in Whitefield as an extension of the flagship center.
2 more points from Healthcare Global Enterprises Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Healthcare Global Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Healthcare Global Enterprises Ltd said on order book & pipeline — free account, 30 seconds.
Healthcare Global Enterprises Ltd — Quarterly revenue & net profit
Healthcare Global Enterprises Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 585 | 495 | +18.3% | 559 | +4.8% |
| Operating profit (EBITDA) | 106 | 92 | +14.8% | 88 | +19.5% |
| Operating margin | 18.05% | 18.61% | -0.6 pp | 15.82% | +2.2 pp |
| Profit before tax | 14 | 28 | -51.7% | -3 | — |
| Net profit (PAT) | 7 | 23 | -71.1% | 8 | -12.6% |
| EPS (₹) | 0.52 | 1.52 | -65.8% | 0.50 | +4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹732 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Healthcare Global Enterprises's management said in earlier quarters
Others in Healthcare Services this season
- 3B Blackbio (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
- Apollo Hospitals (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Narayana Hrudaya (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Healthcare Global Enterprises Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Healthcare Global Enterprises Ltd Q4 FY25 results?
FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores. HCG expects continued strong revenue and EBITDA growth in FY '26, building on a 16-18% revenue growth in FY '25 and a 44% EBITDA increase in emerging centers.
What is Healthcare Global Enterprises Ltd share price analysis?
Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.
Is Healthcare Global Enterprises Ltd planning capital expenditure?
FY '26 Capex planned at approximately INR 286 crores focused on network expansion and technology upgrades, including existing centers in Bangalore and Cuttack.
Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
